This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award provides $274,947 to Lattice Therapeutics Inc. to develop a customizable, next-generation RNA delivery particle. The project aims to create a novel RNA drug delivery platform with implications for treating cancer and other diseases with unmet medical needs. The key products and services to be delivered include:
-
Validating the proof-of-concept for an engineerable protein nanoparticle that can efficiently and specifically deliver RNA cargoes to target cells, including in vitro evaluation of RNA delivery to cancer cells and in vivo delivery to tumor sites.
-
Evaluating the efficacy of therapeutic RNA delivery using this customizable particle platform, positioning it for further clinical development against multiple disease targets.
The project will address limitations of current RNA delivery technologies, with the goal of expanding treatment options for oncology and advancing the nucleic acid delivery market. This SBIR Phase I award runs from July 2024 to June 2025.
Generated 3/4/25, 7:41 AM